The Global Neurology Clinical Trials market size is estimated to reach $5.9 billion by 2026, growing at a CAGR of 3.2% over the forecast period of 2021-2026.

Global Neurology Clinical Trials Market Overview:

A clinical trial is a research investigation in which people can take part. The intention of a clinical trial is to investigate the efficiency of treatment, medicine, experimental drug, or instrument. Clinical trials in the field of neurology constitute Neurology Clinical Trials. Neurology is a branch of medicine handling the ailments of the nervous system.

The leading technological innovations are set to drive the Neurology Clinical Trials Market owing to the enhanced effectiveness and productivity of neurology clinical trials by heightened patient engagement and minimized patient burden accompanied with application of new results.

In addition, the surging innovative practices directed by big pharmaceutical firms in neurology are set to propel the growth of the Neurology Clinical Trials Market during the forecast period.

Impact of COVID-19:

Covid-19 has been an unprecedented event impacting every aspect of businesses worldwide. While the pharma industry is being tapped to help bring out an effective treatment against the pandemic at the earliest, the sector also had the brutal impact of the pandemic.

Especially with the ongoing clinical trials faced delays with disruptions to trial enrolment, data collection, and data analysis. In addition, a combination of lockdown measures and the need to re-prioritize existing healthcare resources in a hospital setting, primarily to focus on Covid-19 patients, are reasons for the slowdown of growth in this market.

Key Takeaways from Global Neurology Clinical Trials Market Report:

• Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units), and Value ($M) data given at country level – for phase, study design, indication, application, and by different industry verticals.
• Understand the different market dynamics – key driving factors, challenges, and hidden opportunities.
• Get in-depth insights on your competitor’s performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT, and more.
• Analyze the sales and distribution channels across key geographies to improve top-line revenues.
• Understand the industry supply chain with a deep dive on the value augmentation at each step to optimize value and bring efficiencies in your processes.
• Get a quick outlook on the market entropy – M&As, deals, partnerships, product launches of all key players for the past four years.
• Evaluate the supply-demand gaps, import-export statistics, and regulatory landscape for more than the top 20 countries globally for the market.

Market Dynamics

Driver:  

Soaring Clinical Trials In Neurology And Neurological Sciences Are Projected To Drive The Growth Of Neurology Clinical Trials Market.

Ingenious clinical trials are being conducted in neurology and neurological sciences by leading educational universities like the Stanford University. BOOST3 (Brain Oxygen Optimization in Severe TBI Phase 3) is an investigation to determine if either of the two approaches for supervising and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU) is more likely to assist them in getting better.

Participants in this investigation are placed arbitrarily in one of 2 groups. One group has medical care based on supervision of pressure in the brain (intracranial pressure or ICP) only. The other group has medical care based on ICP and the quantity of oxygen in the brain (brain tissue oxygen or PbtO2).

It is unrecognized if assessing and treating low brain oxygen is more efficient, less efficient, or the same as supervising and treating high brain pressure only. Treatment varies by group owing to physicians taking decisions led by ICP and PbtO2 objectives.

These decisions involve the types and doses of medicines administered. They also affect the number of liquids administered by vein. These kinds of clinical trials in neurology and neurological sciences are fuelling the growth of the Neurology Clinical Trials Market.

Challenge: 

Restricted Comprehension Of The Elemental Biology Of The Ailment Presents Challenges To The Growth Of The Neurology Clinical Trials Market

The unavailability of the brain makes it difficult to analyze by way of conventional techniques like biopsy. There are insufficient approved molecular targets for most nervous system ailments despite an outburst in elementary neuroscience research, specifically in clinical biology and genetics. Those recognized—primarily for psychiatric conditions like depression, psychosis, and anxiety—are decades old.

The absence of new and approved targets restricts the growth of innovative treatments. The shortage of irresistible biomarkers and novel ailment models limits the capability of examiners to question the pharmacology of investigational compounds across multiple dimensions like behavior, functional, electrophysiological, and so on in proof-of-concept investigations. This issue is hampering the growth of the Neurology Clinical Trials Market.

By phase, the market for Phase III to grow at the highest CAGR during the forecast period.

Phase III is predicted to develop at the fastest rate of XX% during the forecast period, owing to the Phase II trials including a huge count of participants and being the most expensive. As a result, the Phase II segment held the largest market share in 2020.  This growth is because neurological ailments are exceedingly rare, and no particular treatment is accessible.

A typical Phase II trial is a randomized phase II trial that targets to recognize which of two or more treatments is the more encouraging to move into phase III trial. It is therefore termed the ‘pick the winner’ trial. The growing count of Phase II trials is further propelling the growth of the Phase II segment, owing to most trials conducted being Phase II trials.

By Study Design, Neurology Clinical Trials market for Observational segment to grow at the highest CAGR during the forecast period

During the projection period, the Observational segment is estimated to be the fastest-growing, with a CAGR of XX%, owing to the heightening observational study design application in post-marketing security assessments of medications or when clinical trials are not possible. The Interventional Segment held the largest market share in 2020.

This growth is due to the Interventional technique’s accelerated application in conducting a clinical test or experiment. Most investigations have been undertaken about medications or biologics, followed by behavioral, clinical practice, and device intervention analysis. The soaring application of randomized controlled trials in interventional investigations further propels this segment’s growth.

Geographical Overview:

Asia-Pacific to account for the largest market share during the forecast period

North America held the largest share of the Neurology Clinical Trials market in 2020, with a global market share of 36.7%. Due to the raised pervasiveness of neurological ailments and the high concentration of key players like Medpace in the region.

As per the Centers For Disease Control And Prevention (CDC), among those at least 65 years of age, there are 5.0 million adults with dementia in 2014 & projected to be almost 14 million by 2060. Therefore, the expanding predominance of neurological ailments like dementia in conjunction with the expanding population of the elderly is further propelling the growth of the Neurology Clinical Trials Market in the North American region.

The Asia Pacific is also set to be the fastest-growing over 2021-2026. This growth is due to increasing preference for the Asia-Pacific region as the preferred destination for clinical trials. In addition, the upsurge in the initiatives from the government and the grants from academic laboratories are further fuelling the progress of the Neurology Clinical Trials Market in the Asia-Pacific region.

Key Market Players

Key Players in the Global Neurology Clinical Trials Market consist of Novartis, Medpace, Syneous Health, GlaxoSmithKline, Biogen, Convance, Charles River Laboratories, Icon PLC, Aurora Healthcare, IQVIA, among others.

Recent Developments:

• In November 2021, Novartis declared the introduction of its novel innovation hub, Novartis Biome sub-Saharan Africa (SSA), which will lead to the added growth of ingenious business models and technology-driven solutions to enhance healthcare in the region. The hub will spotlight cross-sectoral partnerships to advance innovative techniques to boost affordable access to great-quality medicines and sustainably build up health systems. The introduction backs the bold ambition of the firm to double patient reach in Sub-Saharan Africa by 2022 and expand it five-fold by 2025.

Report Coverage and Scope

The report “Global Neurology Clinical Trials Market” by Research Informatic covers an in-depth detailed analysis for the following segment covered under the scope.

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional
• Observational
• Expanded Access

By Indication

• Epilepsy
• Parkinson’s Disease
• Huntington’s Disease
• Stroke
• Traumatic Brain Injury
• Amyotrophic Lateral Sclerosis
• Muscle Regeneration
• Others

By Application

• Healthcare
• Artificial Tissue & Tissue Regeneration
• Industrial
• Food And Agriculture
• Environmental
• Others

Geography

• North America
• Europe
• APAC
• RoW

Global Neurology Clinical Trials Market Growth, Trend and Forecast 2021-2028

Chapter 1 Neurology Clinical Trials Market Overview
1.1 Product Overview and Scope of Neurology Clinical Trials
1.2 Neurology Clinical Trials Market Segmentation by Type
1.2.1 Global Production Market Share of Neurology Clinical Trials by Type in 2020
1.2.1 Type 1
1.2.2 Type 2
1.2.3 Type 3
1.3 Neurology Clinical Trials Market Segmentation by Application
1.3.1 Neurology Clinical Trials Consumption Market Share by Application in 2020
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 Neurology Clinical Trials Market Segmentation by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India
1.5 Global Market Size (Value) of Neurology Clinical Trials (2014-2028)

Chapter 2 Global Economic Impact on Neurology Clinical Trials Industry
2.1 Global Macroeconomic Environment Analysis
2.1.1 Global Macroeconomic Analysis
2.1.2 Global Macroeconomic Environment Development Trend
2.2 Global Macroeconomic Environment Analysis by Regions

Chapter 3 Global Neurology Clinical Trials Market Competition by Manufacturers
3.1 Global Neurology Clinical Trials Production and Share by Manufacturers (2020 and 2020)
3.2 Global Neurology Clinical Trials Revenue and Share by Manufacturers (2020 and 2020)
3.3 Global Neurology Clinical Trials Average Price by Manufacturers (2020 and 2020)
3.4 Manufacturers Neurology Clinical Trials Manufacturing Base Distribution, Production Area and Product Type
3.5 Neurology Clinical Trials Market Competitive Situation and Trends
3.5.1 Neurology Clinical Trials Market Concentration Rate
3.5.2 Neurology Clinical Trials Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion

Chapter 4 Global Neurology Clinical Trials Production, Revenue (Value) by Region (2014-2021)
4.1 Global Neurology Clinical Trials Production by Region (2014-2021)
4.2 Global Neurology Clinical Trials Production Market Share by Region (2014-2021)
4.3 Global Neurology Clinical Trials Revenue (Value) and Market Share by Region (2014-2021)
4.4 Global Neurology Clinical Trials Production, Revenue, Price and Gross Margin (2014-2021)
4.5 North America Neurology Clinical Trials Production, Revenue, Price and Gross Margin (2014-2021)
4.6 Europe Neurology Clinical Trials Production, Revenue, Price and Gross Margin (2014-2021)
4.7 China Neurology Clinical Trials Production, Revenue, Price and Gross Margin (2014-2021)
4.8 Japan Neurology Clinical Trials Production, Revenue, Price and Gross Margin (2014-2021)
4.9 Southeast Asia Neurology Clinical Trials Production, Revenue, Price and Gross Margin (2014-2021)
4.10 India Neurology Clinical Trials Production, Revenue, Price and Gross Margin (2014-2021)

Chapter 5 Global Neurology Clinical Trials Supply (Production), Consumption, Export, Import by Regions (2014-2021)
5.1 Global Neurology Clinical Trials Consumption by Regions (2014-2021)
5.2 North America Neurology Clinical Trials Production, Consumption, Export, Import by Regions (2014-2021)
5.3 Europe Neurology Clinical Trials Production, Consumption, Export, Import by Regions (2014-2021)
5.4 China Neurology Clinical Trials Production, Consumption, Export, Import by Regions (2014-2021)
5.5 Japan Neurology Clinical Trials Production, Consumption, Export, Import by Regions (2014-2021)
5.6 Southeast Asia Neurology Clinical Trials Production, Consumption, Export, Import by Regions (2014-2021)
5.7 India Neurology Clinical Trials Production, Consumption, Export, Import by Regions (2014-2021)

Chapter 6 Global Neurology Clinical Trials Production, Revenue (Value), Price Trend by Type
6.1 Global Neurology Clinical Trials Production and Market Share by Type (2014-2021)
6.2 Global Neurology Clinical Trials Revenue and Market Share by Type (2014-2021)
6.3 Global Neurology Clinical Trials Price by Type (2014-2021)
6.4 Global Neurology Clinical Trials Production Growth by Type (2014-2021)

Chapter 7 Global Neurology Clinical Trials Market Analysis by Application
7.1 Global Neurology Clinical Trials Consumption and Market Share by Application (2014-2021)
7.2 Global Neurology Clinical Trials Consumption Growth Rate by Application (2014-2021)
7.3 Market Drivers and Opportunities
7.3.1 Potential Applications
7.3.2 Emerging Markets/Countries

Chapter 8 Neurology Clinical Trials Manufacturing Cost Analysis
8.1 Neurology Clinical Trials Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Neurology Clinical Trials

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Neurology Clinical Trials Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Neurology Clinical Trials Major Manufacturers in 2020
9.4 Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

Chapter 11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

Chapter 12 Global Neurology Clinical Trials Market Forecast (2021-2028)
12.1 Global Neurology Clinical Trials Production, Revenue Forecast (2021-2028)
12.2 Global Neurology Clinical Trials Production, Consumption Forecast by Regions (2021-2028)
12.3 Global Neurology Clinical Trials Production Forecast by Type (2021-2028)
12.4 Global Neurology Clinical Trials Consumption Forecast by Application (2021-2028)
12.5 Neurology Clinical Trials Price Forecast (2021-2028)

Chapter 13 Appendix